Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 in developed countries. Understanding of the pathologic process, genetic mechanisms, and risk factors of this disease has the benefit of seeking newer and more effective treatment options. Current clinical therapy for AMD shows a dramatic change from a decade ago. Anti-VEGF drug therapy is regarded as the more effective treatment for neovascular AMD now, especially combining PDT therapy. In the future, the genetic and biochemical therapies may be the promising treatments for AMD. This paper will focus on the progress of pathology, candidate genes of AMD, risk factors, and the existing drugs or surgical therapies available, in order to present some new directions of care with the prospect of improved vision in many patients suffered from AMD. 1. Introduction Age-related macular degeneration (AMD) remains one of the most severe and profound disabilities encountered in medicine, particularly due to the loss of the central vision and the high economic burden it places on patients and societies. AMD is regarded as the most primary cause of blindness, particularly irreversible blindness [1]. The world Health Organization (WHO) summarised the most recent reports which the visual impairment was caused by many common ocular diseases, it was not difficult to find that AMD is the most common cause of blindness. AMD has resulted in the physical and mental health problems of a number of the geriatric population and their families tremendously. Recent years, it was not only high morbidity of AMD in western nations but also progressive incidence in eastern Asia areas, thus, continued research will be critically needed. There were about over one hundred years for scientists to study AMD. Hutchison and Tay published an article named “symmetrical central choroidoretinal disease occurring in senile persons” in 1875. This may be the earliest medical literature about AMD that we can find. We reviewed the basic research towards AMD during about decade. There were three aspects should be summarized, including morphology, molecular biology, and genomics. AMD resulted from many dangerous factors, including genes and environment. With advancing age, some changes occurred in the retina, including alterations in retinal pigment epithelium (RPE) cellular size and shape, thickening of Bruch’s membrane, thickening of the internal limiting membrane, and a decrease in retinal neuronal elements [2]. From a histopathologic standpoint, the initial morphological changes impacted on the photoreceptors
References
[1]
K. M. Gehrs, D. H. Anderson, L. V. Johnson, and G. S. Hageman, “Age-related macular degeneration—emerging pathogenetic and therapeutic concepts,” Annals of Medicine, vol. 38, no. 7, pp. 450–471, 2006.
[2]
R. H. Rosa, B. M. Glaser, Z. De la Cruz, and W. R. Green, “Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-β2, and gas tamponade,” American Journal of Ophthalmology, vol. 122, no. 6, pp. 853–863, 1996.
[3]
W. R. Green, “Histopathology of age-related macular degeneration,” Molecular Vision, vol. 5, p. 27, 1999.
[4]
P. E. Rakoczy, S. H. Sarks, N. Daw, and I. J. Constable, “Distribution of cathepsin D in human eyes with or without age-related maculopathy,” Experimental Eye Research, vol. 69, no. 4, pp. 367–374, 1999.
[5]
S. H. Sarks, J. J. Arnold, M. C. Killingsworth, and J. P. Sarks, “Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study,” British Journal of Ophthalmology, vol. 83, no. 3, pp. 358–368, 1999.
[6]
J. L. Haines, N. Schnetz-Boutaud, S. Schmidt et al., “Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6,” Investigative Ophthalmology and Visual Science, vol. 47, no. 1, pp. 329–335, 2006.
[7]
K. U. Loffler and W. R. Lee, “Basal linear deposit in the human macula,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 224, no. 6, pp. 493–501, 1986.
[8]
G. E. Marshall, A. G. P. Konstas, G. G. Reid, J. G. Edwards, and W. R. Lee, “Type IV collagen and laminin in Bruch's membrane and basal linear deposit in the human macula,” British Journal of Ophthalmology, vol. 76, no. 10, pp. 607–614, 1992.
[9]
T. L. Van der Schaft, C. M. Mooy, W. C. De Bruijn, and P. T. V. M. de Jong, “Early stages of age-related macular degeneration: an immunofluorescence and electron microscopy study,” British Journal of Ophthalmology, vol. 77, no. 10, pp. 657–661, 1993.
[10]
S. H. Sarks, “Ageing and degeneration in the macular region: a clinico pathological study,” British Journal of Ophthalmology, vol. 60, no. 5, pp. 324–341, 1976.
[11]
W. R. Green and C. Enger, “Age-related macular degeneration histopathologic studies: the 1992 Lorenz E. Zimmerman lecture,” Ophthalmology, vol. 100, no. 10, pp. 1519–1535, 1993.
[12]
C. W. Spraul, G. E. Lang, H. E. Grossniklaus, and G. K. Lang, “Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes,” Survey of Ophthalmology, vol. 44, no. 2, pp. S10–S32, 1999.
[13]
S. Sarks, S. Cherepanoff, M. Killingsworth, and J. Sarks, “Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration,” Investigative Ophthalmology and Visual Science, vol. 48, no. 3, pp. 968–977, 2007.
[14]
R. T. Smith, M. A. Sohrab, N. Pumariega et al., “Dynamic soft drusen remodelling in age-related macular degeneration,” British Journal of Ophthalmology, vol. 94, no. 12, pp. 1618–1623, 2010.
[15]
G. S. Hageman, P. J. Luthert, N. H. Victor Chong, L. V. Johnson, D. H. Anderson, and R. F. Mullins, “An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration,” Progress in Retinal and Eye Research, vol. 20, no. 6, pp. 705–732, 2001.
[16]
J. W. Crabb, M. Miyagi, X. Gu et al., “Drusen proteome analysis: an approach to the etiology of age-related macular degeneration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 23, pp. 14682–14687, 2002.
[17]
R. F. Mullins, S. R. Russell, D. H. Anderson, and G. S. Hageman, “Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease,” FASEB Journal, vol. 14, no. 7, pp. 835–846, 2000.
[18]
H. Chen, B. Liu, T. J. Lukas, and A. H. Neufeld, “The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration,” PLoS ONE, vol. 3, no. 6, Article ID e2339, 2008.
[19]
Y. Wang, V. M. Wang, and C. C. Chan, “The role of anti-inflammatory agents in age-related macular degeneration (amd) treatment,” Eye, vol. 25, no. 2, pp. 127–139, 2011.
[20]
P. T.V.M. De Jong, “Age-related macular degeneration,” New England Journal of Medicine, vol. 355, no. 14, pp. 1474–1485, 2006.
[21]
R. Brancato, U. Introini, L. Pierro et al., “Optical coherence tomography (OCT) in retinal angiomatous proliferation (RAP),” European Journal of Ophthalmology, vol. 12, no. 6, pp. 467–472, 2002.
[22]
M. C. Donati, G. Carifi, G. Virgili, and U. Menchini, “Retinal angiomatous proliferation: association with clinical and angiographic features,” Ophthalmologica, vol. 220, no. 1, pp. 31–36, 2005.
[23]
M. A. Hunter, M. T. Dunbar, and P. J. Rosenfeld, “Retinal angiomatous proliferation: clinical characteristics and treatment options,” Optometry, vol. 75, no. 9, pp. 577–588, 2004.
[24]
X. Ding, M. Patel, and C. C. Chan, “Molecular pathology of age-related macular degeneration,” Progress in Retinal and Eye Research, vol. 28, no. 1, pp. 1–18, 2009.
[25]
S. Zareparsi, K. E. H. Branham, M. Li et al., “Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration,” American Journal of Human Genetics, vol. 77, no. 1, pp. 149–153, 2005.
[26]
Y. P. Conley, A. Thalamuthu, J. Jakobsdottir et al., “Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy,” Human Molecular Genetics, vol. 14, no. 14, pp. 1991–2002, 2005.
[27]
D. F. Conrad, D. Pinto, R. Redon et al., “Origins and functional impact of copy number variation in the human genome,” Nature, vol. 464, no. 7289, pp. 704–712, 2010.
[28]
R. M. Ahuja, J. D. Benner, J. C. Schwartz, J. W. Butler, and S. M. Steidl, “Efficacy of transpupillary thermotherapy (TTT) in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration,” Seminars in Ophthalmology, vol. 16, no. 2, pp. 81–85, 2001.
[29]
M. A. Zarbin, “Current concepts in the pathogenesis of age-related macular degeneration,” Archives of Ophthalmology, vol. 122, no. 4, pp. 598–614, 2004.
[30]
D. Kent and C. Sheridan, “Choroidal neovascularization: a wound healing perspective,” Molecular Vision, vol. 9, pp. 747–755, 2003.
[31]
J. Bradley, M. Ju, and G. S. Robinson, “Combination therapy for the treatment of ocular neovascularization,” Angiogenesis, vol. 10, no. 2, pp. 141–148, 2007.
[32]
G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D. Hanahan, “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,” Journal of Clinical Investigation, vol. 111, no. 9, pp. 1287–1295, 2003.
[33]
X. Yang, J. Hu, J. Zhang, and H. Guan, “Polymorphisms in CFH, HTRA1 and CX3CR1 confer risk to exudative age-related macular degeneration in Han Chinese,” British Journal of Ophthalmology, vol. 94, no. 9, pp. 1211–1214, 2010.
[34]
A. Kassoff, J. Kassoff, J. Buehler et al., “A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8,” Archives of Ophthalmology, vol. 119, no. 10, pp. 1417–1436, 2001.
[35]
J. M. Seddon, J. Cote, and B. Rosner, “Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake,” Archives of Ophthalmology, vol. 121, no. 12, pp. 1728–1737, 2003.
[36]
M. Ip, A. Kroll, and E. Reichel, “Transpupillary thermotherapy,” Seminars in Ophthalmology, vol. 14, no. 1, pp. 11–18, 1999.
[37]
E. Reichel, A. M. Berrocal, M. Ip et al., “Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration,” Ophthalmology, vol. 106, no. 10, pp. 1908–1914, 1999.
[38]
A. A. Hussain, Y. Lee, J. J. Zhang, and J. Marshall, “Disturbed matrix metalloproteinase activity of Bruch's membrane in age-related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 52, no. 7, pp. 4459–4466, 2011.
[39]
R. S. B. Newsom, J. C. McAlister, M. Saeed, and J. D. A. McHugh, “Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation,” British Journal of Ophthalmology, vol. 85, no. 2, pp. 173–178, 2001.
[40]
Y. Yu, T. R. Bhangale, J. Fagerness et al., “Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration,” Human Molecular Genetics, vol. 20, no. 18, pp. 3699–3709, 2011.
[41]
X. Liu, P. Zhao, S. Tang et al., “Association study of complement factor H, C2, CFB, and C3 and age-related macular degeneration in a Han Chinese population,” Retina, vol. 30, no. 8, pp. 1177–1184, 2010.
[42]
L. Dong, Y. Qu, H. Jiang et al., “Correlation of complement factor H gene polymorphisms with exudative age-related macular degeneration in a Chinese cohort,” Neuroscience Letters, vol. 488, no. 3, pp. 283–287, 2011.
[43]
B. Vojnikovi？, S. Synek, V. Mi？ovi？, M. Tele？ar, and Z. Lin？ak, “Epidemiological study of sun exposure and visual field damage in children in Primorsko-Goranska County—the risk factors of earlier development of macular degeneration,” Collegium Antropologicum, vol. 34, supplement 2, pp. 57–59, 2010.
[44]
F. Jonasson, A. Arnarsson, H. Sasaki, T. Peto, K. Sasaki, and A. C. Bird, “The prevalence of age-related maculopathy in Iceland: reykjavik eye study,” Archives of Ophthalmology, vol. 121, no. 3, pp. 379–385, 2003.
[45]
A. Ostenfeld-？kerblom, “Age-related macular degeneration in Inuit,” Acta Ophthalmologica Scandinavica, vol. 77, no. 1, pp. 76–78, 1999.
[46]
P. Mitchell, W. Smith, K. Attebo, and Jie Jin Wang, “Prevalence of age-related maculopathy in Australia: the blue mountains eye study,” Ophthalmology, vol. 102, no. 10, pp. 1450–1460, 1995.
[47]
L. Xu, S. Wang, Y. Li, and J. B. Jonas, “Retinal vascular abnormalities and prevalence of age-related macular degeneration in adult Chinese: the Beijing Eye study,” American Journal of Ophthalmology, vol. 142, no. 4, pp. 688–689, 2006.
[48]
S. Synek, B. Vojnikovi？, and D. Pahor, “Epidemiology and quality of life of patients with age-related macular degeneration,” Collegium Antropologicum, vol. 34, supplement 2, pp. 25–28, 2010.
[49]
B. Mu？oz, R. Klein, J. Rodriguez, R. Snyder, and S. K. West, “Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: proyecto VER,” Archives of Ophthalmology, vol. 123, no. 11, pp. 1575–1580, 2005.
[50]
B. Mu？oz, R. Klein, J. Rodriguez, R. Snyder, and S. K. West, “Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: proyecto VER,” Archives of Ophthalmology, vol. 123, no. 11, pp. 1575–1580, 2005.
[51]
U. Chakravarthy, T. Y. Wong, A. Fletcher et al., “Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis,” BMC Ophthalmology, vol. 10, no. 1, article 31, 2010.
[52]
R. D. Sperduto, L. A. Yannuzzi, J. A. Sorenson et al., “Risk factors for neovascular age-related macular degeneration,” Archives of Ophthalmology, vol. 110, no. 12, pp. 1701–1708, 1992.
[53]
A. F. Cruess, G. Zlateva, A. M. Pleil, and B. Wirostko, “Photodynamic therapy with verteporfin in age-related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties,” Acta Ophthalmologica, vol. 87, no. 2, pp. 118–132, 2009.
[54]
J. Mataix, M. Carmen Desco, E. Palacios, M. Garcia-Pous, and A. Navea, “Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study,” Ophthalmic Surgery Lasers and Imaging, vol. 40, no. 3, pp. 277–284, 2009.
[55]
K. Sonmez, P. A. Sonmez, S. S. Ozkan, and L. S. Atmaca, “One-year outcomes of less frequent bevacizumab in age-related macular degeneration,” Retina, vol. 31, no. 4, pp. 645–653, 2011.
[56]
K. D. Kovacs, M. T. Quirk, T. Kinoshita et al., “A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration,” Retina, vol. 31, no. 3, pp. 446–452, 2011.
[57]
J. B. Jonas, Y. Tao, and F. C. Schlichtenbrede, “Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice,” Journal of Ocular Pharmacology and Therapeutics, vol. 27, no. 5, pp. 467–470, 2011.
[58]
C. Trempe, “Ranibizumab for age-related macular degeneration,” New England Journal of Medicine, vol. 364, no. 6, pp. 581–582, 2011.
[59]
T. L. S？rensen and H. Kemp, “Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision,” Acta Ophthalmologica, vol. 89, no. 1, p. e97, 2011.
[60]
C. Schmucker, Y. K. Loke, C. Ehlken et al., “Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review,” British Journal of Ophthalmology, vol. 95, 308 pages, 2010.
[61]
A. Chiang and C. D. Regillo, “Preferred therapies for neovascular age-related macular degeneration,” Current Opinion in Ophthalmology, vol. 22, no. 3, pp. 199–204, 2011.
[62]
M. H. Berrocal, M. L. Lewis, and H. W. Flynn, “Variations in the clinical course of submacular hemorrhage,” American Journal of Ophthalmology, vol. 122, no. 4, pp. 486–493, 1996.
[63]
J. L. Borrillo and C. D. Regillo, “Treatment of subretinal hemorrhages with tissue plasminogen activator,” Current Opinion in Ophthalmology, vol. 12, no. 3, pp. 207–211, 2001.
[64]
C. I. Falkner, H. Leitich, F. Frommlet, P. Bauer, and S. Binder, “The end of submacular surgery for age-related macular degeneration? A meta-analysis,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 245, no. 4, pp. 490–501, 2007.
[65]
P. V. Algvere and S. Seregard, “Age-related maculopathy: pathogenetic features and new treatment modalities,” Acta Ophthalmologica Scandinavica, vol. 80, no. 2, pp. 136–143, 2002.
[66]
P. A. Campochiaro, “Retinal and choroidal neovascularization,” Journal of Cellular Physiology, vol. 184, no. 3, pp. 301–310, 2000.
[67]
N. S. Dejneka, A. Auricchio, A. M. Maguire et al., “Pharmacologically regulated gene expression in the retina following transduction with viral vectors,” Gene Therapy, vol. 8, no. 6, pp. 442–446, 2001.
[68]
D. W. Dawson, O. V. Volpert, P. Gillis et al., “Pigment epithelium-derived factor: a potent inhibitor of angiogenesis,” Science, vol. 285, no. 5425, pp. 245–248, 1999.
[69]
N. M. Holekamp, N. Bouck, and O. Volpert, “Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration,” American Journal of Ophthalmology, vol. 134, no. 2, pp. 220–227, 2002.
[70]
E. J. Duh, H. S. Yang, I. Suzuma et al., “Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth,” Investigative Ophthalmology and Visual Science, vol. 43, no. 3, pp. 821–829, 2002.
[71]
T. K. MacLachlan, M. Lukason, M. Collins et al., “Preclinical safety evaluation of AAV2-sFLT01- A gene therapy for age-related macular degeneration,” Molecular Therapy, vol. 19, no. 2, pp. 326–334, 2010.
[72]
M. Honda, T. Sakamoto, T. Ishibashi, H. Inomata, and H. Ueno, “Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration,” Gene Therapy, vol. 7, no. 11, pp. 978–985, 2000.
[73]
H. L. Kong, D. Hecht, W. Song et al., “Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor,” Human Gene Therapy, vol. 9, no. 6, pp. 823–833, 1998.
